CVMClinical•businesswire•
FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
Sentiment:Positive (80)
Summary
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HNSCC--FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 18, 2025 by businesswire